Paquinimod

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Paquinimod
Accession Number
DB13118  (DB05901)
Type
Small Molecule
Groups
Investigational
Description

Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease. The disease affects mainly women of fertile age and progresses in flares with relatively symptom free periods in between. Current treatments of SLE are NSAID (nonsteroidal anti-inflammatory drugs), corticosteroids, antimalarians or cytotoxic drugs like for example Cyclophosphamide. The autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses.

Structure
Thumb
Synonyms
Not Available
External IDs
ABR-215757
Categories
UNII
HB76GLG27V
CAS number
248282-01-1
Weight
Average: 350.418
Monoisotopic: 350.163042576
Chemical Formula
C21H22N2O3
InChI Key
DIKSYHCCYVYKRO-UHFFFAOYSA-N
InChI
InChI=1S/C21H22N2O3/c1-4-14-10-9-13-16-17(14)19(24)18(20(25)22(16)3)21(26)23(5-2)15-11-7-6-8-12-15/h6-13,24H,4-5H2,1-3H3
IUPAC Name
N,5-diethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
SMILES
CCN(C(=O)C1=C(O)C2=C(CC)C=CC=C2N(C)C1=O)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Paquinimod.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paquinimod.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Paquinimod.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Paquinimod.Approved
FingolimodPaquinimod may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Paquinimod.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Paquinimod.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Paquinimod.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Paquinimod.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Paquinimod.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Paquinimod.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Paquinimod is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Paquinimod is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Paquinimod.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Paquinimod is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Paquinimod.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Paquinimod.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Paquinimod.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Paquinimod.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Paquinimod.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Paquinimod.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paquinimod.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Paquinimod.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Paquinimod.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Paquinimod.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Paquinimod.Investigational
TofacitinibPaquinimod may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Paquinimod.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Paquinimod.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Paquinimod.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
54684617
PubChem Substance
347829241
ChemSpider
11444964
ChEMBL
CHEMBL67776

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedBasic ScienceSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentSclerosis, Progressive Systemic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0653 mg/mLALOGPS
logP2.74ALOGPS
logP2.91ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)6.28ChemAxon
pKa (Strongest Basic)-2.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.85 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity102.15 m3·mol-1ChemAxon
Polarizability37.59 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aromatic anilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with an aromatic group. They have the general structure RNC(=O)R', where R= benzene, and R = aryl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Aromatic anilides
Alternative Parents
Quinoline-3-carboxamides / Hydroquinolones / Hydroxyquinolines / Hydroquinolines / Pyridinecarboxylic acids and derivatives / Hydroxypyridines / Pyridinones / Tertiary carboxylic acid amides / Vinylogous acids / Vinylogous amides
show 7 more
Substituents
Aromatic anilide / Quinoline-3-carboxamide / Dihydroquinolone / Hydroxyquinoline / Dihydroquinoline / Quinoline / Pyridine carboxylic acid or derivatives / Hydroxypyridine / Pyridinone / Pyridine
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 21:20 / Updated on November 09, 2017 05:18